Alphyn Biologics (Alphyn) is a privately held limited liability company.  Alphyn has an experienced, successful international leadership team and exceptional operational partners and advisory boards that include key thought leaders, researchers, and practitioners in dermatology, skin diseases, infectious disease, oncology, regulatory approvals, and the life science and consumer industries.

Our Investors, Financing, and Use of Proceeds

Alphyn recently closed a Series A financing round of approximately $3.3 million, bringing the total raised to about $6.7 million. Series A investors include Queen City Angels, the Angel Physicians Fund, and Serial Stage Venture Partners. Family office investment funds, a corporate partner and private investors with medical, life science industry, and legal backgrounds participated in the company’s earlier rounds.

If you are interested in learning more about Alphyn, or for financial or investment inquiries, please contact Neal Koller at +1 (410) 690-8687 or use the form below:

    Yes, please add me to Alphyn’s email list.

    PRESS RELEASES

    Coming Soon

    NEWS, EVENTS, PRESENTATIONS

    Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

    Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…

    Read more

    Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

    Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Oct 18, 2022, 07:30 ET Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced…

    Read more

    Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment

    Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment Over-subscribed round to support Phase2a clinical trial in atopic dermatitis ANNAPOLIS, MD, September 15, 2022 – Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3…

    Read more

    CEO and Chairman of Alphyn Biologics talks with CONNECTpreneur Anchor and Phoenix Fund General Partner

    Neal Koller, CEO and Chairman of Alphyn Biologics, talks with Laura Hill, CONNECTpreneur Anchor and Phoenix Fund General Partner in Tysons Corner, Virginia in February, 2020 Alphyn is a life science company developing proprietary drug therapy for treating serious skin diseases. The initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based…

    Read more

    BIO International 2019

    BIO International 2019 Alphyn was selected to present at BIO International 2019 on June 6, 2019, in Philadelphia, Pennsylvania.  Chairman & CEO Neal Koller presented.

    Read more